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Summary
We report a low molecular weight inhibitor ofa-amylases
based on a linear peptidic scaffold designed de novo
through the use of combinatorial chemistry. The inhib-
itory motif denoted PAMI (peptide amylase inhibitor)
was selected by using L-peptide libraries and was
fine-tuned by the introduction of unnatural modifica-
tions. PAMI specifically inhibits glycoside hydrolases
of family 13. Its interaction with porcine pancreatic
a-amylase was characterized by inhibition kinetics,
fluorescence competition assays with naturala-amylase
inhibitors, and isothermal titration calorimetry. We
demonstrate that the critical amino acid residues in
PAMI are shared with those in the macromolecular pro-
teinaceous inhibitors that, however, bind toa-amylases
through a spatially scattered set of intermolecular con-
tacts. Thus, natural molecular evolution as well as com-
binatorial evolution selected the same a-amylase
binding determinants for completely different spatial
frameworks.
Introduction
a-amylases (a-1,4-glucan-4-glucanohydrolases) are a
group of glycoside hydrolases widely distributed in mi-
croorganisms, plants, and animal tissues. They catalyze
the hydrolysis of the a-(1,4) glycosidic linkage found in
starch components and other related polysaccharides.
a-amylases are among the oldest known enzymes; how-
ever, detailed information about their structure and inhi-
bition started to come to light only in the ’90s as they
became a target for regulation of important physiologi-
cal processes. Currently, there are two major applica-
tions of a-amylase inhibitors. Orally given a-amylase
inhibitors, such as the antidiabetic drug acarbose, sup-
press postprandial glucose levels in diabetic patients
(for a review, see [1]). The second promising field is the
potential use of a-amylase inhibitors in transgenic crops
to suppress the development of insect pests through the
impairment of their amylolytic digestion (for a review,
see [2]).
The natural inhibitors of a-amylases comprise oligo-
saccharide inhibitors of the trestatin family fromStrepto-
myces that contain the acarviosine moiety (e.g., acar-
bose) and proteinaceous inhibitors isolated from
microbial sources and plant tissues [3, 4]. The plant in-
hibitors have two main functions: they regulate endoge-
*Correspondence: mares@uochb.cas.cznousa-amylase activity in seeds, or they act as defensive
proteins directed against exogenous digestive a-amy-
lases of insect herbivores [2]. The a-amylase inhibitors
of protein character compose seven structurally differ-
ent protein families, and, for five of them, X-ray struc-
tures of the complexes with a-amylase were determined
thus far [5–9]. These spatial models revealed that the
structural mechanism of inhibitory complex formation
with the target enzyme evolved in a specific way for
each family of the inhibitors. As the proteinaceous a-am-
ylase inhibitors are strong ligands (with inhibition con-
stants mostly in nanomolar range), their binding is
generally established through an extended set of inter-
molecular contacts with several segments of the poly-
peptide chain involved in the binding. Due to the compli-
cated architecture, the rational design of small inhibitory
mimetics of these macromolecular ligands is a diffi-
cult task. However, this problem can be efficiently ap-
proached through the application of combinatorial tech-
nologies to generate vast molecular diversities and
select de novo ligand structures. The first attempts to
use a combinatorial repertoire for the development of
a-amylase inhibitors were done recently with the phage
display method, but this effort led to novel ligands having
the macromolecular protein scaffold [10, 11]. Interest-
ingly, the powerful approach of combinatorial chemistry
that is very successful in the development of novel low-
molecular weight therapeutics has not been applied for
this purpose thus far.
To our knowledge, we report the first low-molecular
weight inhibitory motif for a-amylases designed de
novo through the use of combinatorial chemistry. The
structural requirements and interaction mode of the dis-
covered inhibitory ligands were characterized in detail
by kinetic, fluorescence, and calorimetric methods. This
analysis revealed that the small peptidic recognition
motif represents a molecular mimicry of the macromo-
lecular a-amylase inhibitors, as it effectively arranges the
analogous structural determinants in a simple, linear
scaffold. Finally, unnatural derivatives of the lead pep-
tide inhibitor were developed as more potent a-amylase
inhibitors than the antidiabetic drug acarbose [3] or
small a-amylase ligands constructed by rational design
[12, 13].
Results
De Novo Design of the a-Amylase Inhibitory Motif
Porcine pancreatic a-amylase (PPA) was used as a tar-
get enzyme for the screening of inhibitory activity of
combinatorial L-peptide libraries by using a standard
assay with chromogenic substrate Remazol Brilliant
Blue-dyed starch (RBB-Starch). In the first step, we pre-
pared 400 sublibraries with 2 fixed amino acids at the
N terminus in the format Ac-B1B2XXXX-NH2 (B, defined
position; X, randomized position). Screening of sublibrar-
ies for PPA inhibition guaranteed the selection of
the most effective inhibitory mixture, Ac-HWXXXX-NH2
(Figure 1). In the next step, preference for the third posi-
tion was studied with a library of second generation
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ies, leading to the most efficient sublibrary, Ac-
HWYXXX-NH2 (Table 1). Analogously, an iterative selec-
tion process was performed to sequentially define the
remaining X positions in the C-terminal direction with li-
braries Ac-HWYB4XX-NH2 to Ac-HWYYRB6-NH2. This
procedure gradually improved the inhibitory potential
of the derived combinatorial ligands and identified the
hexapeptide core with sequence HWYYRC, which dis-
played an IC50 value in the micromolar range (Table 1).
The inhibition potency was further improved by extend-
ing the core in the N- and C-terminal directions with
libraries Ac-HWYYRCB7-NH2 and Ac-B8HWYYRCW-
NH2. The delineated sequence GHWYYRCW represents
Figure 1. Combinatorial Design of the a-Amylase Inhibitory Motif
PAMI
(A) Structure of the lead peptide molecule GHWYYRCW-NH2 se-
lected through the complete procedure (comp. I) and its unnatural
tosyl derivative with improved inhibitory potency (comp. II).
(B) The first step in the selection procedure: screening of 400 pep-
tide sublibraries of the Ac-B1B2XXXX-NH2 structure for inhibition of
PPA activity. The most inhibitory sublibrary, Ac-HWXXXX-NH2, is
highlighted. ‘‘B’’ indicates the defined position with 1 of 20 pro-
teinogenic L-amino acids, and ‘‘X’’ indicates the random position
with an equimolar mixture of 20 proteinogenic L-amino acids; val-
ues are expressed as the percentage of activity relative to the
uninhibited control. PPA (10 pM) was assayed at pH 6.9 with the
chromogenic substrate Remazol Brilliant Blue-dyed starch (0.3%,
w/v) and 50 mg/ml peptides.the octapeptide motif for a-amylase inhibition further
denoted as PAMI (peptide amylase inhibitor) (Figure 1).
In Table 1, we also present results on an alternative
branch of the iterative procedure split in the B3 position
for which Trp residue was approaching the efficiency of
the most inhibitory Tyr residue. Interestingly, this selec-
tion process resulted in identification of the hexapeptide
sequence HWWRCW that closely resembles the se-
quence obtained for the Tyr branch (HWYYRC); how-
ever, this sequence is frame shifted by one residue. It
appears that the structural block of WYYR might be
functionally equivalent to the WWR block concerning
its contribution to the binding.
Unnatural Modification of the Inhibitory Motif
To further improve its efficiency, the PAMI motif was
modified by specific unnatural substitutions and by con-
formational changes of its scaffold. A panel of the deriv-
atives and their inhibitory potency are listed in Table 2.
First, the position of structurally distinct determinants
of Arg5 and Cys6 was studied. The side chain of arginine
was modified by Pmc or a tosyl group, both containing
an aromatic moiety with a sulfonyl group, which resulted
in the improvement of the inhibition by an order of mag-
nitude. On the other hand, the substitution of arginine
with citrulline totally abolished the inhibition, suggesting
that the guanidino group cannot be substituted by its
isosteric urea homolog. Modification of the cysteine
side chain with an apolar t-butyl group or a polycyclic ar-
omate fluorescein did not dramatically change the inhi-
bition. However, an introduction of the polar group of
Table 1. Iterative Scheme to Define the a-Amylase Inhibitory
Motif PAMI
Library Sublibrary IC50 (mM)
a
Ac-B1B2XXXX-NH2 Ac-HWXXXX-NH2 w200
Ac-HWB3XXX-NH2 Ac-HWYXXX-NH2 107.5
Ac-HWWXXX-NH2 95.3
Y3 Iteration
Ac-HWYB4XX-NH2 Ac-HWYYXX-NH2 35.3
Ac-HWYYB5X-NH2 Ac-HWYYRX-NH2 27.4
Ac-HWYYRB6-NH2 Ac-HWYYRW-NH2 20.5
Ac-HWYYRC-NH2 16.2
Ac-HWYYRCB7-NH2 Ac-HWYYRCL-NH2 12.2
Ac-HWYYRCR-NH2 10.7
Ac-HWYYRCY-NH2 10.1
Ac-HWYYRCW-NH2 6.3
Ac-B8HWYYRCW-NH2 Ac-WHWYYRCW-NH2 4.8
Ac-YHWYYRCW-NH2 4.5
Ac-GHWYYRCW-NH2 4.1
W3 Iteration
Ac-HWWB4XX-NH2 Ac-HWWRXX-NH2 33.4
Ac-HWWRB5X-NH2 Ac-HWWRCX-NH2 28.5
Ac-HWWRCB6-NH2 Ac-HWWRCW-NH2 25.3
Ac-HWWRCR-NH2 16.4
The sublibraries most inhibitory against PPA are listed with the IC50
values determined. ‘‘B’’ indicates the defined position with 1 of 20
proteinogenic L-amino acids, and ‘‘X’’ indicates the random position
with an equimolar mixture of 20 proteinogenic L-amino acids. The Y3
and W3 iterations represent two parallel branches of the iterative
scheme derived from the Ac-HWB3XXX-NH2 library with two potent
inhibitory sublibraries (B3 = Y or W).
a The peptide libraries were screened for inhibition of PPA activity in
an assay with 10 pM enzyme and 0.3% (w/v) Remazol Brilliant Blue-
dyed starch as substrate at pH 6.9.
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Structurea IC50 (mM)
b,c
Ac-/Alkyl- NH2-
Arg and Cys substitution
HWYYR(Tos) C 1.7 6 0.3
GHWYYR(Tos)CW comp. II 2.6 6 1.2 0.5 6 0.2
GHWYYR(Tos)C(tBu)W 1.9 6 0.4
HWYYCitrC n.s.i.
GHWYYR(Pmc)CW 0.9 6 0.3
GHWYYR(Pmc)C(Acm)W 5.1 6 1.1
GHWYYRC(Acm)W 171.2 6 23.5
GHWYYRC(tBu)W 6.1 6 2.0 6.8 6 1.9
GHWYYRC(Flu)W comp. IV 7.6 6 1.4
Tyr-Tyr substitution
GHWZ(Tpc)Z(Tpc)RCW 125.1 6 17.3
GHWZ(Tpg)Z(Tpg)RCW 173.9 6 19.1
GHWF(pCl)F(pCl)RCW 178.3 6 21.8
GHWA(cHx)A(cHx)RCW 115.2 6 18.4
GHWWRCW 12.4 6 2.2
Terminus modification
GHWYYRCW-COOH 4.2 6 0.4 4.6 6 1.1
GHWYYRCW comp. I 4.1 6 0.9 5.1 6 0.9
Flu-GHWYYRC(tBu)W comp. III 19.6 6 3.1
Lac(C8)-GHWYYRCW n.s.i.
Scaffold modification
GHWYYRCW-gAbu-GHWYYRCW 0.5 6 0.2 1.6 6 0.3
GHWYYRCW 8.3 6 1.5
GHWYYRCW
CGHWYYRC(tBu)WC n.s.i.
D-amino acid substitution
ghwyyrcw 171.8 6 8.5
The modified peptides (0–250 mM) were assayed with 10 pM enzyme and 0.3% (w/v) RBB-Starch as substrate at pH 6.9. The compounds were
synthesized in the form of peptidyl amides containing a free (NH2-) or acetylated (Ac-) N terminus, or they were modified at the N terminus by
attachment of a specified group. The compounds referred to in the text are indicated (comp. I–IV).
a R(Tos), tosyl-arginine; C(tBu), t-butyl-cysteine; R(Pmc), 2,2,5,7,8-pentamethyl-chromane-6-sulfonyl-arginine; Citr, citruline; C(Acm), acetami-
domethyl-cysteine; Z(Tpc), 4-aminotetrahydropyran-carboxylic acid; Z(Tpg), tetrahydropyran-4-yl-glycine; F(pCl), p-chloro-phenylalanine;
A(cHx), cyklohexylalanine; C(Flu), fluorescein- acetamido-cysteine; Flu, fluoresceinyl; Lac(C8), mono(lactosylamido)suberyl; gAbu, 4-aminobu-
tyric acid; Ac, acetyl.
b n.s.i., no significant inhibition with 250 mM peptide.
c6SE of the mean of triplicates is indicated.Acm resulted in about a 40-fold loss of inhibition. Sec-
ond, the aromatic cluster of two tyrosine residues was
replaced by unnatural cyclic blocs, which significantly
decreased the inhibitory effect. This points to the impor-
tance of the arrangement of aromatic residues in the
PAMI motif. Third, the charge at the N and C termini of
PAMI had no significant effect on inhibition, similar to
what occurs with bulky group attachment to the N termi-
nus. Interestingly, PAMI was completely inactivated
when coupled at the N terminus to a disaccharide unit
through an aliphatic linker. Fourth, the PAMI motif com-
posed of L-amino acids was globally converted to the
D-peptide conformation. It resulted in significantly de-
creased, but not eliminated, inhibition, which implicates
the flexibility of side chains in partially compensating for
the switch in conformation. The cyclization of peptidic
structure had a more dramatic effect, and it completely
inactivated the PAMI inhibitor. On the contrary, the di-
merization of the PAMI motif did not negatively influence
its inhibitory properties, as shown by clustering two
peptides in a linear arrangement (with a gAbu linker) or
via a disulfide bond formed between Cys residues of
the motif. These results suggest that the unconstrained
conformation of the linear PAMI motif is essential for its
efficient binding to a-amylase.Inhibitory Specificity
The PAMI motif was discovered by using the selection
procedure with PPA as a target. Its inhibitory specificity
was investigated by using glycoside hydrolases of differ-
ent substrate specificities covering a-amylases and a-
glucosidases of mammalian, insect, fungal, and bacterial
origin, as well as other selected a- and b-glycosidases
functioning in an exo or endo mode of action (Table 3).
The analysis showed that all a-amylases and some of
the a-glucosidases tested were sensitive to inhibition.
The explanation for this pattern came through classifica-
tion of the screened enzymes according to membership
to different structural families of glycoside hydrolases:
all sensitive enzymes belong to family 13, while insensi-
tive enzymes belong to the other seven families tested.
We do not exclude the possibility that PAMI may exert in-
hibition toward an additional family among a vast num-
ber of glycoside hydrolase families not included in the
screening (see the CAZy database, [14]). In summary,
the PAMI motif is probably a family-selective inhibitor
that can best recognize the common structural features
in the binding clefts of a-amylases and a-glucosidases
of family 13. Our screening also shows that various
PAMI derivatives differ in their IC50s when tested with dif-
ferent sensitive enzymes (data not shown).
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A kinetic analysis was performed to determine the inhi-
bition type of PAMI. The hydrolysis of substrate p-nitro-
phenyl-a-D-maltoheptaoside-4,6-O-ethylidene by PPA
follows standard Michaelis-Menten kinetics with a KM =
85 mM and a kcat of 226 s
21. The initial rates of product
formation in the presence of PAMI inhibitor are shown
in a double-reciprocal Lineweaver-Burk plot (Figure 2).
The family of straight lines intersects in the second quad-
rant, which indicates a noncompetitive inhibition of
mixed type. The secondary plots suggest an involve-
ment of more complex kinetic features, as the slope re-
plot is parabolic (Figure 2). Our experimental data on
the kinetics of PAMI inhibition agree with the previous
observation of mixed noncompetitive inhibition associ-
ated with nonstandard secondary plots, as reported for
PPA inhibition by the natural inhibitors acarbose and
aAI-1 [15, 16]. The inhibition constant of Ki = 2.5 mM
was determined for PAMI from the slope plot, and this
Table 3. Screening of the PAMI Derivative Ac-GHWYYRCW for
Inhibition of Activity of Model Glycoside Hydrolases
Enzyme Origin IC50 (mM)
a
GH
Class
a-amylase porcine pancreas 4.1 6 0.9 13
human saliva 3.2 6 0.2 13
Tenebrio molitor 1.1 6 0.1 13
Aspergillus oryzae 1.7 6 0.2 13
Bacillus amyloliquefaciens 3.1 6 0.4 13
Bacillus licheniformis 2.2 6 0.1 13
Bacillus subtilis 8.3 6 0.4 13
a-glucosidase Bacillus stearothermophilus 19.2 6 0.9 13
Saccharomyces cerevisiae 2.0 6 0.3 13
Schizosaccharomyces
pombe
n.s.i. 31
porcine liver n.s.i. 31
porcine intestine n.s.i. 31
b-glucosidase sweet almonds n.s.i. 1
b-galactosidase Escherichia coli >250 2
cellulase Trichoderma viride n.s.i. 7
b-amylase sweet potato n.s.i. 14
chitinase Streptomyces griseus >250 18
a-mannosidase almonds n.s.i. 38
The structural class of glycoside hydrolases tested is indicated (GH
class) according to the CAZy database [14]. n.s.i., no significant in-
hibition with 250 mM peptide. 6SE of the mean of triplicates is indi-
cated.
a For details on particular activity assays, see Experimental Proce-
dures.value compares well with an IC50 of 4.1 mM obtained by
using dye-labeled starch as a macromolecular substrate
(Table 1).
Fluorescence Binding Studies
The interaction of PPA with PAMI (comp. I) was investi-
gated by monitoring the changes in emission intensity of
intrinsic tryptophan fluorescence, as both molecules
contain tryptophan residues. PAMI and PPA display
emission spectra with a maximum at 350 nm. Formation
of the complex was associated with the quenching of
fluorescence intensity at this wavelength, as evidenced
by the comparison of the spectrum of the complex with
that obtained as the sum of individual spectra for PPA
and PAMI (Figure 3A). The PAMI concentration was
kept at least 100 times higher than the PPA concentra-
tion to achieve saturation levels for complex formation
and maximum changes in fluorescence intensity. The
observed quenching suggests that tryptophan residues
of the PAMI and/or PPA molecule are involved in the en-
zyme-inhibitor interaction. In order to analyze the topol-
ogy of PAMI binding to the PPA surface, the competition
experiments were performed by using two natural inhib-
itors, aAI-1 and acarbose, for which the binding mode is
well-documented by X-ray structures [5, 17] (Figure 3A).
The proteinaceous inhibitor aAI-1 interacts with a large
region that surrounds the substrate binding site of
PPA [2]. In accord, we found that it completely displaced
PAMI from its complex with PPA due to high affinity of
aAI-1 (10211 M order) [18]. The concentration-depen-
dent competition effect was observed for acarbose, an
oligosaccharide inhibitor with an inhibitory constant in
the micromolar range, which occupies five substrate
binding subsites in the PPA active site [16, 17]. The per-
formed analysis suggests that PAMI binds to PPA inside
the region covered by aAI-1 and, more precisely, at
some of the substrate binding subsites occupied by
the substrate analog acarbose.
Fluorescence polarization experiments were used to
determine the equilibrium dissociation constant for the
PAMI and PPA complex [19]. For this purpose, we syn-
thesized two fluorescein-labeled PAMI ligands (comps.
III and IV) having different attachment sites of the fluores-
cein moiety (Table 2). The inhibition screening experi-
ments showed that both derivatives have similar inhibi-
tory potency as compared to the unlabeled PAMI
(comp. I) (Table 2). The labeled ligands were used in sat-
uration binding experiments monitored by fluorescenceFigure 2. Kinetic Analysis of PPA Inhibition
by PAMI
The Lineweaver-Burk plot for inhibition of
PPA with PAMI (comp. I) is indicative of a
mixed-type, noncompetitive inhibition. Activ-
ity of 1.1 nM enzyme was measured at pH 6.9
in the presence of 0–4 mM inhibitor and 0.1–
0.5 mM substrate p-nitrophenyl-a-D-malto-
heptaoside-4,6-O-ethylidene. The secondary
plots for the same data set indicated nonstan-
dard kinetic features with a linear y intercept
replot and a parabolic slope replot. The inhibi-
tion constant of Ki = 2.5 mM was determined
from the slope replot. Error bars depict 6SE
of the mean of triplicates.
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PAMI Binding to PPA
(A) Quenching of intrinsic tryptophan fluores-
cence upon the formation of a complex be-
tween PAMI and PPA, and modulation of this
signal by competition with natural a-amylase
inhibitors acarbose (Aca) or the bean inhibitor
(aAI-1). (1) Control experiments on complexa-
tion of PPA with individual inhibitors, (2) com-
plexation of PPA with a mixture of acarbose
and PAMI at the molar ratio indicated, (3)
complexation of PPA with a mixture of aAI-1
and PAMI at a molar ratio of 1:100 (aAI-1:
PAMI). Note that PAMI and acarbose are mi-
cromolar inhibitors and that aAI-1 is a subna-
nomolar inhibitor of PPA. The inset figure
shows the fluorescence emission spectra of
PPA (solid line), PAMI (dotted line), and the
complex of PPA with PAMI (dashed line).
The dashed and dotted line represents the
sum of individual spectra for PPA and PAMI.
The concentrations of PPA and PAMI (comp.
I) were 0.3 mM and 30 mM, respectively. Error
bars depict 6SE of the mean of triplicates.
(B) Fluorescence polarization assay of PAMI
binding to PPA plotted as fraction of the li-
gand bound. Left: titration of PPA against
a constant concentration of fluorescein-labeled PAMI (comp. III) (50 nM) revealed the optimized parameter Kd = 9.26 0.9 mM. Right: competitive
displacement of the fluorescein-labeled PAMI (10 nM) complexed with PPA (10mM) by unlabeled PAMI (comp. I) revealed the optimized parameter
Kd = 5.0 6 0.3 mM.anisotropy, and an analogous behavior was recorded for
both compounds. Figure 3B represents a typical titration
curve of PPA against the constant concentration of
fluorescein-labeled PAMI for which a Kd of 9.2 mM was
calculated. Further, the fluorescence polarization tech-
nique was applied in a competition assay between fluo-
rescein-labeled and unlabeled PAMI (Figure 3B). PPA
and the labeled ligand at preselected constant concen-
trations were incubated with various concentrations of
PAMI to yield a Kd of 5.0 mM for the unlabeled ligand.
Calorimetric Analysis of Binding
The energetics of the association between PAMI and a-
amylase were studied by isothermal titration calorimetry.
Figure 4 shows titration of PPA with PAMI (comp. II) per-
formed in two buffers with different ionization enthalpies.
The observed enthalpy was plotted as a function of the
molar ratio of PAMI to PPA, yielding the ligand to enzyme
binding stoichiometry of 1.08. The binding strength of
PAMI calculated from the plot corresponds to the asso-
ciation constant KA = 1.653 10
5 M21 (Kd of 6.1 mM). The
apparent reaction enthalpy measured during the reac-
tion comprises the binding enthalpy and the enthalpy
of ionization of the buffer used in the experiment. By per-
forming identical titration experiments in two buffer sys-
tems with known ionization enthalpy, it was possible to
determine an involvement of a protonation event during
complex formation and to calculate the net binding en-
thalpy, which is buffer independent (see Experimental
Procedures). This revealed that two protons (w1.83)
are released during binding of PAMI to PPA. The binding
enthalpy (DHbinding =210.8 kcal/mol) and the final calcu-
lated entropy parameter (2TDSbinding = 3.7 kcal/mol)
indicated that binding of PAMI to PPA is favored by
enthalpic and disfavored by entropic contributions to
Gibbs energy of binding (DGbinding = 27.1 kcal/mol).Discussion
To our knowledge, we undertook for the first time the de-
sign of a low-molecular weight inhibitor of a-amylases
by using a combinatorial chemistry approach. The com-
binatorial technique proved to provide a powerful tool
for de novo creation of a structural motif complementary
to the a-amylase active site cleft. The linear peptidic
scaffold was chosen, as it represents a versatile tem-
plate that allows for additional unnatural modifications
by means of chemical synthesis and it can be applied
in expression systems.
Figure 4. Isothermal Titration Calorimetry of Binding of PAMI to PPA
The heat signal was corrected for the heat of dilution and was plotted
as the observed enthalpy versus the molar ratio of PAMI to PPA. The
experiment was performed with 650 mM PAMI (comp. II) injected
stepwise to 67 mM PPA at pH 6.9 in MES buffer (circles) and sodium
cacodylate buffer (stars), respectively, at 25ºC. The parameters
determined: stoichiometry = 1.08 6 0.03, Kd = 6.1 6 0.2 mM, proton
release = 1.83 6 0.17, DHbinding = 210.8 kcal/mol 6 0.2, and
2TDSbinding = 3.7 kcal/mol 6 0.2.
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an inhibitory strength in the low micromolar range (Table
1), and it reached a submicromolar level after incorpora-
tion of a simple, unnatural substitution (IC50 of 0.5 mM for
comp. II, Table 2). The potency of PAMI thus surpasses
that of the natural oligosaccharide acarbose used in di-
abetes treatment [16, 20] as well as cyclic peptides de-
veloped by rational design [12, 21]. For acarbose, we
measured an IC50 of 3.8 mM for PPA by using the same
assay as for PAMI, and similar low micromolar inhibition
was reported for human pancreatic and salivary a-amy-
lases [16, 20, 22]. The cyclic peptides were derived from
a b turn loop participating in the interaction of the pro-
teinaceous a-amylase inhibitor Tendamistat with the en-
zyme active site [12, 21]. These b turn derivatives are
about 3 orders of magnitude less potent ligands than
PAMI, and this low potency clearly shows difficulties in
approaching this problem by a conventional way and
demonstrates an advantage of the de novo design. Ten-
damistat and other proteinaceous a-amylase inhibitors
are nanomolar (or better) ligands whose binding strength
and high degree of selectivity for a-amylases are based
on the formation of an extended set of intermolecular
contacts with the target enzyme. These multiple con-
tacts are formed on a large binding interface where the
macromolecular inhibitor interacts through several spa-
tially separated segments of its folded polypeptide
chain. In the case of aAI-1, the total buried area in the
complex with PPA is about 3050 A˚2 (contributed by
both molecules), one of the largest reported values for
a protein-protein complex [5]. In this context, it is not sur-
prising that the low-molecular weight inhibitor PAMI, in-
teracting with glycoside hydrolases from family 13, dis-
plays both lower potency and broader selectivity than
the proteinaceous a-amylase inhibitors. On the other
hand, PAMI is more selective than the oligosaccharidic
a-amylase inhibitors that are crossrecognized by several
families of glycoside hydrolases [3].
To describe the PAMI interaction mode, we investi-
gated its binding to PPA as a model a-amylase by using
enzyme kinetics, fluorescence spectroscopy methods,
as well as isothermal titration microcalorimetry. The
magnitude of the dissociation constant in the low micro-
molar range determined by fluorescence study and mi-
crocalorimetry is very close to the magnitude of the inhi-
bition constant obtained through the kinetic analysis.
The intrinsic fluorescence measurements were per-
formed to investigate PAMI binding in competition with
the natural a-amylase inhibitors aAI-1 and acarbose
that were previously characterized with respect to their
binding mode by kinetic [15, 16] and X-ray studies
[5, 17]. Our analysis clearly demonstrated that PAMI in-
teracts with a-amylase in such a way that it occupies at
least some of its substrate binding subsites. The ther-
modynamic characterization of PAMI revealed that its
binding is favored by enthalpic and disfavored by entro-
pic contributions to binding. The negative value deter-
mined for the binding enthalpy of PAMI is fairly low
and compares well with similar values reported for other
good ‘‘enthalpic inhibitors.’’ Interestingly, these inhibi-
tors also include low-molecular weight saccharidic in-
hibitors such as acarbose, tetrahydrooxazines, and imi-
nosaccharides, whose interaction with glucoamylase
and b-glucosidase was recently analyzed by microcalo-rimetry [23–25]. Thus, the peptidic inhibitor PAMI dis-
plays an analogous thermodynamic signature with sac-
charidic (i.e., substrate-like) inhibitors of glycoside
hydrolases. The critical enthalpic contribution to PAMI
binding suggests that a net of intermolecular interac-
tions based on hydrogen and van der Waals bonding
is formed during PAMI complexation. The analysis of
ionization enthalpy showed that a transfer of two pro-
tons (from the inhibitor-enzyme complex to the bulk so-
lution) is coupled with the binding. Hence, ionic interac-
tions can also be involved in the formation of the
complex. The origin of released protons is impossible
to determine, as ionizable groups are present in the
PAMI as well as the PPA binding site.
Recently published X-ray analysis of a representative
collection of the complexes of proteinaceous a-amylase
inhibitors showed that five structurally unrelated modes
of binding to a-amylase evolved in different protein fam-
ilies [5–9]. We examined these structures and discov-
ered a high content of aromatic and arginine residues
at the binding interface of three nonhomologous a-amy-
lase inhibitors. Thus, Tendamistat, aAI-1, and Amaranth
inhibitors (PDB accessions 1BVN, 1DHK, and 1CLV, re-
spectively) form about 40% of the intermolecular con-
tacts in the respective complexes through these struc-
tural determinants (for BASI and Ragi inhibitors [1AVA
and 1TMQ], this number is lower, with w30% and
10%, respectively, of the intermolecular contacts). Such
a fraction represents a significant part of the 15–40 con-
tact residues identified to be responsible for binding of
these inhibitors to a-amylases [5–7]. Importantly, argi-
nine and aromatic residues comprise about 75% of the
amino acid residues in the sequence of the PAMI pep-
tide, and their critical importance for inhibition was dem-
onstrated in this study with substituted derivatives of
PAMI. Judging from the three-dimensional structures
available, we assume that this set of key inhibitory resi-
dues reflects the composition of the complementary
binding area on the a-amylase surface that is rich in
acidic (including the catalytic triad Asp/Glu/Asp) and ar-
omatic residues. Interestingly, the same inhibitory resi-
dues were recently reported to be involved in inhibition
of chitinases (family 18 of glycoside hydrolases) by nat-
ural cyclopentapeptide inhibitors [26]. Taken together,
the critical inhibitory determinants in the small PAMI
motif are shared with those in the macromolecular pro-
teinaceous inhibitors of a-amylases. Thus, natural mo-
lecular evolution of proteins as well as combinatorial
evolution of their peptidic mimetics selected the same
structural determinants, but arranged them in different
spatial frameworks to establish effective interaction
with the target enzyme.
The PAMI motif accomplishes the selective interac-
tion with a-amylases in a highly effective manner by us-
ing a small peptidic scaffold with an unconstrained
linear conformation. Its structure allows for various ap-
plications, including potential synthetic therapeutics or
its use in expression systems to produce a recombinant
peptide inhibitor or peptide fusion tag that introduces
the inhibitory functionality into a carrier protein of inter-
est. The identified PAMI motif represents a lead com-
pound of the first generation that opens the way for fur-
ther modulation of its properties by combinatorial and
rational methods after determination of its exact binding
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complex is currently underway.
Significance
a-amylases became an important pharmacological tar-
get for treatment of diabetes as well as a plant biotech-
nology target for suppression of insect pests. The nat-
ural a-amylase inhibitors of protein character have
attracted much attention, followed by small-molecule
inhibitors of new structures and defined properties,
which are now in demand. Herein, we report the first,
to our knowledge, low-molecular weight inhibitory mo-
tif active against a-amylases, called PAMI, that was de-
signed de novo through the use of combinatorial
chemistry. We provide a comprehensive description
of its structural requirements and interaction with the
target enzymes. This analysis revealed that the small
peptidic recognition motif with a simple linear scaffold
represents an effective molecular mimicry of the mac-
romoleculara-amylase inhibitors. The discovered syn-
thetic derivatives of PAMI are more potent inhibitors of
pancreatic a-amylases than the natural antidiabetic
drug acarbose, and they represent promising lead
compounds for therapeutic application. Further, PAMI
is a good inhibitor of insect digestive a-amylases, and
its synthetic gene is an attractive candidate for modifi-
cation of crops to increase their resistance.
Experimental Procedures
Materials
The commercial enzymes used were a-amylases from porcine
pancreas, human saliva, B. amyloliquefaciens, A. oryzae (Sigma,
St.Louis, MO);B. subtilis andB. licheniformis (Fluka, Buchs, Switzer-
land); a-glucosidases from S. cerevisiae and B. stearothermophillus
(Sigma); b-galactosidase from E. coli and chitinase from S. griseus
(Fluka); cellulase from T. viride, b-amylase from sweet potato, and
a-mannosidase from almonds (Sigma); and b-glucosidase from
sweet almonds (Serva, Heidelberg, Germany). The a-glucosidases
from S. pombe and porcine intestine were donated by P. Karasova
(Institute of Chemical Technology, Praha), and porcine liver a-gluco-
sidase was donated by I. Kluh (Institute of Organic Chemistry and
Biochemistry, Praha). The activity assay substrate p-nitrophenyl-
a-D-maltoheptaoside-4,6-O-ethylidene was purchased from Boeh-
ringer Manheim (Manheim, Germany), and other saccharidic sub-
strates containing the p-nitrophenyl or 4-methylumbelliferyl groups
were purchased from Sigma. Remazol Brilliant Blue-dyed starch
(RBB-Starch) and OBR-hydroxyethyl-cellulose dyed with Ostazin
Brilliant Red were purchased from Fluka, and Chitin azure dyed
with Remazol Brilliant Violet and soluble potato starch were pur-
chased from Sigma. The a-amylase inhibitor acarbose was pur-
chased from Bayer (Leverkusen, Germany), and the aAI-1 inhibitor
from Phaseolus vulgaris was purified as described previously [27].
The Fmoc precursors of L- and D-amino acids were obtained from
NovaBiochem (Darmstadt, Germany), and other building blocks for
peptide synthesis were obtained from Neosystem (Strasbourg,
France). The D-1600 resin (Bachem, Bubendorf, Switzerland) was
used for combinatorial synthesis, and Wang resin (NovaBiochem)
and TentaGel S RAM resin (Rapp polymere, Tubigen, Germany)
were used for conventional peptide synthesis.
Preparation of Peptides and Peptide Libraries
The primary library of soluble L-amino acid hexapeptide mixtures,
Ac-B1B2XXXX-NH2, was synthesized in dual-positional format. The
defined position B contained one of the arrays of 20 proteinogenic
amino acids, and the randomized position X contained an equimolar
mixture of 20 proteinogenic amino acids. Formats for iterative L-
amino acid hexa- to octapeptide libraries were Ac-O1O2B3XXX-NH2 to Ac-O1O2O3O4O5B6-NH2, Ac-O1O2O3O4O5O6B7-NH2, and
Ac-B8O1O2O3O4O5O6O7-NH2, where the defined B position and the
random X position is as explained above; the fixed O position con-
tained 1 of 20 proteinogenic amino acids invariant for the particular
library. Fmoc solid-phase chemistry and the split combinatorial
method were used for the library synthesis [28, 29]. Peptide libraries
were cleaved from solid support and were deprotected by the TFA
procedure, ether extracted, and lyophilized. The peptides derived
from PAMI were prepared by standard Fmoc synthetic machinery
on an ABI 433A Peptide Synthesizer (Applied Biosystems, Foster
City, CA) in the form of peptidyl amides containing a free or acety-
lated N terminus [30]. The modification of the free N terminus of
GHWYYRC(tBu)WC-NH2 with lactose derivative was performed
postsynthetically with mono(lactosylamido) mono(succinimidyl)-
suberate (Pierce, Rockford, IL) according to the manufacturer’s pro-
tocol. The cyclization of C(Acm)GHWYYRC(tBu)WC(Acm)-NH2 and
the dimerization of GHWYYRC(Acm)WC-NH2 was accomplished in
solution by disulfide formation between S-acetamidomethyl (Acm)
cysteines after their deprotection by the iodine oxidation protocol
[31]. The fluorescence derivatives of GHWYYRC(tBu)WC-NH2 and
Ac-GHWYYRCWC-NH2 were postsynthetically modified by fluores-
cein isothiocyanate and 5-(iodoacetamido)fluorescein (Sigma), re-
spectively, according to the manufacturer’s protocol. All PAMI deriv-
atives were purified by reverse-phase HPLC on a Vydac C18 column
(218TP510, Vydac, Hesperia, CA) equilibrated in 0.1% (v/v) trifluoro-
acetic acid at a flow rate of 3 ml/min, and they were eluted with a 1%/
min gradient of 90% (v/v) acetonitrile solution in 0.1% (v/v) trifluoro-
acetic acid. The purified peptides were characterized by ESI mass
spectrometry on a LCQ Classic Finnigan Mat (Thermo Finnigan, Bre-
men, Germany).
Inhibition Assays
Porcine pancreatic a-amylase (PPA) (10 pM) was preincubated for
10 min at 26ºC with a peptide library (0.1–50 mg/ml) in 50 mM MES
buffer (pH 6.9) containing 5 mM CaCl2, 2% DMF, and 0.1 M NaCl
(pH 6.9 buffer). The residual activity of PPA was determined with
0.3% (w/v) RBB-Starch as a substrate. After 20 min of incubation
at 26ºC, the reaction was stopped by 0.2 M NaOH, and the mixture
was centrifuged. The absorbance of the supernatant was measured
at 620 nm. Purified peptides in the range of 0–250 mM were used for
determination of IC50 values. Other a-amylases were screened in the
same assay: the particular enzyme concentration was set to give the
same substrate conversion rate as for PPA, and the reaction mixture
was buffered with 0.1 M sodium acetate buffer (pH 5.0) containing
5 mM CaCl2, 2% DMF, and 50 mM NaCl. The inhibition assay of b-
amylase with soluble, unlabeled potato starch (0.5%) as a sub-
strate was performed with the neocuprine method at pH 5.5 [15].
The inhibition of cellulase from T. viride (at pH 5.0) and chitinase
from S. griseus (at pH 5.5) was tested in an activity assay with the
suspension substrates OBR-hydroxyethyl-cellulose (0.5%) and Chi-
tin azure (0.1%), respectively, under a protocol recommended by the
substrate manufacturer. The inhibition assay for a-glucosidases, b-
glucosidase, and b-galactosidase was performed with substrates p-
nitrophenyl-a-D-glucopyranoside (7 mM), p-nitrophenyl-b-D-gluco-
pyranoside (3.5 mM), and p-nitrophenyl-b-D-galactopyranoside
(0.1 mM), respectively. Generally, the enzyme (1 U/ml) was preincu-
bated (20 min at 26ºC) with peptide (0–250 mM) in 0.1 M sodium phos-
phate buffer (pH 6.8) containing 2% DMF (for a-glucosidases from
S. cerevisiae, B. stearothermophillus, and porcine intestine) or
0.1 M sodium acetate buffer (pH 4.5) containing 2% DMF (for a-glu-
cosidases from S. pombe and porcine liver) or in the latter buffer (pH
5.5) (for b-glucosidase and b-galactosidase). The kinetics of p-nitro-
phenol release was continuously monitored in a GENios Plus
(TECAN, Salzburg, Austria) microplate reader at 405 nm. By defini-
tion, one activity unit liberates an amount of chromogenic product
that gives A405 = 1 in 1 hr. An analogous continuous assay was used
for the inhibition assay of a-mannosidase with 4-methylumbelliferyl-
a-D-mannopyranoside substrate (30 mM) performed at pH 5.5 by
monitoring the fluorescent product (lex = 360 nm, lem = 465 nm).
The stock solutions of peptides and peptide mixtures applied in in-
hibition assays were quantified by amino acid analysis on Biochrom
20 (Amersham Biosciences, Uppsala, Sweden). All measurements
were performed in triplicate.
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Determination of inhibition type was accomplished by using an activ-
ity assay with p-nitrophenyl-a-D-maltoheptaoside-4,6-O-ethylidene
as a substrate [32]. A mixture of 1.1 nM PPA and 0–4 mM PAMI
(comp. I) was preincubated for 10 min at 26ºC in 50 mM MES buffer
(pH 6.9) containing 5 mM CaCl2, 2% DMF, and 0.1 M NaCl. The re-
action was started by the addition of 0.05–0.5 mM substrate and
was allowed to proceed for three time intervals to determine initial
velocity. The p-nitrophenol chromogen was released from digested
fragments of substrate by a conversion reaction [32], and the
p-nitrophenol concentration was determined from absorbance at
405 nm.
Fluorescence Measurements
The fluorescence measurements were performed with an Aminco-
Bowman Series 2 Luminiscence spectrometer (Thermo Electron,
Cambridge, UK). For intrinsic fluorescence analysis, an excitation
wavelength of 280 nm and an emission wavelength in the range of
300–400 nm were used. The emission spectrum was recorded sep-
arately for PPA (0.3 mM), PAMI (comp. I) (30 and 150 mM), acarbose
(5–150 mM), aAI-1 (0.3 mM), and their defined mixtures. The solutions
were buffered by 50 mM MES buffer (pH 6.9) containing 5 mM CaCl2,
5% DMF, and 0.1 M NaCl. The mixtures were incubated for 1 hr at
25ºC to allow the mixture to reach the equilibrium. As output data,
the sum of PPA and individual inhibitors’ emission spectra was com-
pared with the spectrum of their mixture [33]. The percent quenching
(Q) of intrinsic fluorescence was calculated by using equation:
Q= (12
Isample
Ifree
)100, (1)
where Ifree is the sum of the fluorescence intensities of individual
components before mixing, and Isample is the fluorescence intensity
measured for the mixture of components. The measurement per-
formed at 350 nm giving a maximum emission signal was corrobo-
rated by the integrated signal over the range of 300–400 nm. Fluores-
cence polarization analysis was performed with fluorescein-labeled
PAMI (comp. III or IV) at 25ºC by using excitation and emission wave-
lengths of 485 nm and 530 nm, respectively. Anisotropy titration was
carried out with 50 nM fluorescein-labeled ligand and 0–50 mM PPA
in 50 mM MES buffer (pH 6.9) containing 5 mM CaCl2, 5% DMF, and
0.1 M NaCl. The mixture of the labeled ligand and PPA was incu-
bated for 1 hr at 25ºC to reach the equilibrium. The fluorescence of
the buffer alone was subtracted from each measurement, and the
anisotropy was calculated according to Lakowicz [34]. G factor
correction was performed by using fluorescein as a standard. The
anisotropy data were converted to the fraction of the ligand bound
by using equation:
fb =
robs2 r0
(robs 2 r0) +R(rmax2 robs)
, (2)
where fb is the fraction of the ligand bound and robs, r0, and rmax are
the observed anisotropy, anisotropy of the free ligand, and the an-
isotropy of the ligand bound to saturating amounts of PPA, respec-
tively. R is the fluorescence intensity of the fluorophore saturated
with PPA divided by the intensity of the free fluorophore. The Kd of
the probe binding to PPA was determined by nonlinear least-square
fit to a single-site binding model by using software Grafit (Erithacus
software, Surrey, UK). Competition experiments were carried out
analogously as described above with 10 mM PPA and a mixture of
50 nM fluorescein-labeled PAMI (comp. III or IV) and 0–40 mM
PAMI (comp. I). The concentration of stock solutions applied was
determined by amino acid analysis (PAMIs, PPA) and elementary
analysis (acarbose).
Titration Microcalorimetry
Binding of PAMI (comp. II) to PPA was monitored in a VP-ITC titra-
tion microcalorimeter (Microcal, Inc., Northampton, MA) at 25ºC.
The solutions of reactants were prepared in 25 mM MES (or sodium
cacodylate) (pH 6.9) containing 5 mM CaCl2 and 5% DMF, and their
concentrations were determined by amino acid analysis. Aliquots
(9 ml) of 650 mM PAMI were stepwise injected into a sample cell con-
taining 1.43 ml of 67 mM PPA until complete saturation. Each exper-
iment was accompanied by the corresponding control experiment inwhich PAMI was injected into buffer alone. The heat due to the bind-
ing reaction between the inhibitor and the enzyme was obtained as
the difference between the measured heat of the reaction and the
corresponding heat of the dilution determined in the control exper-
iment [35]. The thermodynamic parameters, stoichiometry, and KA
values were calculated by ORIGIN 5.0 sofware (Microcal, Inc.). A
proton transfer between the binding complex and the buffer mole-
cules was evaluated by performing the titration experiments in two
buffers with different ionization enthalpies (3.72 kcal/mol for the
MES buffer, 20.47 kcal/mol for the cacodylate buffer) [36]. The cal-
culation of parameters Dn and DHbinding was performed essentially
as described previously [37] according to:
DHITC =DHbinding +DnDHion, (3)
where Dn is the number of transferred protons upon binding,
DHbinding is the buffer-independent binding enthalpy, DHion is the
ionization enthalpy of buffer, and HITC is the apparent enthalpy.
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